CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
CASI Pharmaceuticals, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
48.6%+11.4 pts over 5 years
Operating margin
-217.3%+131.3 pts over 5 years
Net margin
-232.0%+86.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -27.4% | -21.7% | +6.5% | – | |
| Gross profit | -9.6% | -28.3% | +12.3% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -62.5% | 271.3% | |
| Return on assets | – | – | -121.2% | |
| Current ratio | – | – | 0.27 | |
| Interest coverage | – | -17026.1× | – | |
| Inventory turnover | – | – | 3.1× | |
| Capex to revenue | – | 9.9% | 0.1% | |
| Diluted shares | – | 11M | 19M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CASI Pharmaceuticals generated $117.88M from operations and spent $18.55M on capital expenditure, dividends and share buybacks. 81% of that went back into the business.
Generated
$117.88M
Used
$18.55M
Capital expenditure$15.00M81%Dividends$00%Share buybacks$3.55M19%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-232.0%
×Asset turnover0.52×
×Equity multiplier-2.24×
=Return on equity, FY2025271.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -232.0% | 0.52× | -2.24× | 271.3% |
| FY2024 | -137.6% | 0.44× | 4.96× | -301.8% |
| FY2023 | -79.6% | 0.40× | 2.49× | -78.4% |
| FY2022 | -95.1% | 0.37× | 1.82× | -63.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$48.06M
- Cash generatingOperating cash flow above zero-$20.75M
- Return on assets improvedROA up on the prior year-52.2% → -89.5%
- Earnings backed by cashOperating cash flow above net income-$20.75M vs -$48.06M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.09 → 0.27
- No dilutionShare count did not rise15M → 19M
- Gross margin improvedGross margin up on the prior year39.06% → 48.65%
- More efficientAsset turnover rose0.38 → 0.39